BiotechTube

ASP1707 + Placebo + Leuprorelin acetate

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Endometriosis

Conditions

Endometriosis

Trial Timeline

Dec 4, 2012 → Jul 30, 2015

NCT ID
NCT01767090

About ASP1707 + Placebo + Leuprorelin acetate

ASP1707 + Placebo + Leuprorelin acetate is a phase 2 stage product being developed by Astellas Pharma for Endometriosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01767090. Target conditions include Endometriosis.

What happened to similar drugs?

1 of 19 similar drugs in Endometriosis were approved

Approved (1) Terminated (3) Active (15)
✅Decapeptyl SR 11.25mgIpsenApproved
🔄40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetateSumitomo PharmaPhase 3
🔄Elagolix + Placebo + Combined Oral ContraceptiveAbbViePhase 3
🔄Estradiol/Norethindrone Acetate + Placebo for Elagolix + Elagolix + Placebo for E2/NETAAbbViePhase 3
🔄ElagolixAbbViePhase 3
❌elagolix + estradiol/norethindrone acetate (E2/NETA)AbbViePhase 3
🔄ElagolixAbbViePhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01767090Phase 2Completed

Competing Products

20 competing products in Endometriosis

See all competitors
ProductCompanyStageHype Score
40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetateSumitomo PharmaPhase 3
47
SHR7280 TabletsJiangsu Hengrui MedicinePhase 1
29
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
29
SHR7280 + Placebo oral tabletJiangsu Hengrui MedicinePhase 1/2
32
SHR7280 Tablet + SHR7280 Placebo TabletJiangsu Hengrui MedicinePhase 1
29
Placebo + ElagolixAbbViePhase 2
35
Elagolix + Placebo + Combined Oral ContraceptiveAbbViePhase 3
44
Estradiol/Norethindrone Acetate + Placebo for Elagolix + Elagolix + Placebo for E2/NETAAbbViePhase 3
40
ElagolixAbbViePhase 3
40
elagolix + estradiol/norethindrone acetate (E2/NETA)AbbViePhase 3
32
Elagolix + placeboAbbViePhase 2
35
ElagolixAbbViePhase 3
40
Elagolix + Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) + Placebo to Elagolix + Placebo to DMPA-SCAbbViePhase 2
35
elagolixAbbViePhase 3
40
ElagolixAbbViePhase 3
40
Leuprorelin Acetate Depot + Elagolix + Placebo to Elagolix + Placebo to Leuprorelin AcetateAbbViePhase 2
35
Gefapixant + Placebo + NaproxenMerckPhase 2
35
BGS649 + PlaceboNovartisPhase 2
27
Active treatment with a high dose of BGS649 + Active treatment with a low dose of BGS649 + Placebo treatment to blind studyNovartisPhase 2
35
LetrozoleNovartisPhase 2
35